HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on peptides and GLP-1. Browse all Peptides & GLP-1 education

"It didn't work for me" is the most common sentence in peptide and hormone communities. Not because peptide protocols don't work — the clinical literature on GLP-1 receptor pathways, growth hormone axis, androgen signaling, and estrogen clearance is substantial. But because generic protocols assume that every person's biology responds to the same pathway intervention the same way. That assumption is false. The same compound targets the same pathway in every person — but the genes governing that pathway are not the same in every person. The Precision Peptide Genetic Test was designed to close this gap, analyzing 14 pathways, 49 peptides, and 150+ genetic insights to reveal where your biology diverges from the population average — before you commit to a protocol.

The Biology of Individual Response

Every peptide protocol works through a specific biological mechanism. GLP-1 receptor agonists bind GLP-1 receptors to modulate appetite and glucose metabolism. Growth hormone secretagogues stimulate pituitary GH release, which drives IGF-1 production downstream. Androgen replacement protocols raise testosterone, which binds androgen receptors in target tissues. The mechanism is identical in every person — but the sensitivity of the receptors, the efficiency of the enzymes, the rate of downstream metabolite conversion, and the translation of those signals into biological effects varies significantly by genetics. That genetic variance is why population-average protocols produce population-average results for some people and nothing for others.

Weight Management — Why the Same Metabolic Protocol Hits Differently

The GLP-1 receptor pathway involves at least six genetically variable systems: appetite regulation (FTO), satiety signaling (MC4R), GLP-1 receptor sensitivity (GLP1R), glucose metabolism (TCF7L2), fat storage and insulin response (PPARG), and GIP receptor pathway engagement (GIPR). Two people on the same weight management protocol can experience dramatically different outcomes because their genetic baseline in each of those systems differs. Someone with a high-risk FTO variant and attenuated GLP1R sensitivity faces a meaningfully different metabolic landscape than someone without those variants — and the same protocol won't move both people the same distance. The Precision Peptide Genetic Test maps 34 Weight Management insights to quantify exactly that variation.

Longevity — Why the Same Stack Doesn't Age Everyone the Same Way

Longevity protocols work through pathways that are genetically differentiated at every level: cellular stress response (FOXO3), mitochondrial antioxidant defense (SOD2), lipid and cognitive aging trajectory (APOE), sirtuin-mediated DNA repair (SIRT1), and telomere maintenance (TERT). Someone with favorable FOXO3 variants and efficient SOD2 activity starts from a meaningfully different baseline than someone with less favorable profiles — and the same NAD+ pathway support or GH-releasing agent will deliver a different leverage ratio. The 17 Longevity & Aging insights in the panel map that baseline before a single protocol dollar is spent. For the full gene-by-gene breakdown, see the Complete Guide to Genetic Longevity Testing.

Muscle Growth — Why the Same Program Produces Different Results

Two people follow identical training, eat identical diets, and use the same growth hormone axis support. One adds significant lean mass. The other barely moves. The genetic explanation usually involves three layers: ACTN3 R577X genotype determines whether fast-twitch or slow-twitch fiber architecture is dominant; GHSR and GHR variants determine how efficiently growth hormone signals translate into downstream IGF-1; and MSTN determines the myostatin ceiling on total muscle mass. A protocol calibrated to a specific ACTN3/GHSR/GHR profile will outperform one calibrated to population averages. For the full breakdown, see the Complete Guide to Genetic Muscle Growth Testing.

Men's Hormone — Why the Same Protocol Feels Different in Different Men

"Normal" testosterone means different things in different men — and the same androgen replacement protocol produces different outcomes because of it. SHBG variants determine how much testosterone is bioavailable versus carrier-bound. CYP19A1 variants determine how aggressively testosterone converts to estrogen. AR CAG repeat length determines how sensitively tissues respond to the androgen signal. SRD5A2 variants determine DHT conversion rate. Two men with identical total testosterone and the same protocol can have completely different experiences because their genetic architecture differs in all four systems simultaneously. For the full breakdown, see the Complete Guide to Genetic Men's Hormone Testing.

Women's Hormone — Why the Same Dose Lands Differently

Estrogen replacement that produces textbook outcomes in one woman can produce entirely different experiences in another at the same dose — and clearance genetics explain most of that variance. CYP1A1 and CYP1B1 determine the ratio of estrogen metabolites produced in Phase 1. COMT determines methylation speed in Phase 2. MTHFR determines methylation capacity that COMT depends on. ESR1 and ESR2 determine tissue receptor sensitivity. A woman with slow-COMT, slow-MTHFR, and high-sensitivity ESR1 is in a completely different hormonal position than a woman with the opposite profile — at identical circulating estradiol levels and the same prescribed dose. For the full breakdown, see the Complete Guide to Genetic Women's Hormone Testing.

The Common Thread — And What to Do About It

Every one of these failure modes — in weight management, longevity, muscle growth, men's hormone, women's hormone, and sexual health — has the same root cause: the protocol was designed for the average person, and you are not the average person. Population-average protocols are built on population-average response curves. For the fraction of people who sit at the tails of those curves — faster metabolizers, slower clearers, more sensitive receptors, less responsive receptor sites — the average protocol produces below-average results. Genetic testing doesn't guarantee above-average results; it shifts the starting point from population average to individual baseline. For the full case on why testing first changes this equation, see our post on Test Before You Invest.

Genetics as a Guide, Not a Guarantee

Genetic testing doesn't guarantee a protocol will work — no test can do that. What it does is raise the probability that the protocol you and your healthcare provider choose is calibrated to your actual biological architecture rather than a population-average assumption. A favorable ACTN3 R577X genotype doesn't guarantee muscle growth; it tells you that fast-twitch fiber composition is an asset to build on. A fast-COMT genotype doesn't guarantee estrogen balance; it tells you that clearance capacity is a strength rather than a liability. The Precision Peptide Genetic Test maps 14 pathways and 150+ insights so that every protocol decision can start from a better-informed position. That's the entire premise of testing before you invest.

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand what your genes say about your peptide response? Take the Precision Peptide Genetic Test

Frequently Asked Questions

Why don't peptide protocols work the same for everyone?

Genetic variation. The same compound targets the same pathway in every person — but the genes governing that pathway differ between individuals. FTO, FOXO3, ACTN3, SHBG, and COMT variants mean weight management, longevity, muscle, and hormone biology are tuned differently in everyone. The Precision Peptide Genetic Test maps 14 pathways and 150+ individual differences.

What makes some people respond better to peptide protocols?

Genetics, primarily. Higher GHR receptor sensitivity means more downstream IGF-1 response per unit of growth hormone input. Faster CYP19A1 aromatase means more estrogen management is needed in hormone protocols. Shorter AR CAG repeats produce stronger androgen signaling at the same testosterone level. The Precision Peptide Genetic Test reveals 150+ individual differences across 14 pathways.

How does genetic testing help avoid failed peptide protocols?

Genetic testing reveals how your biology differs from the population average before you commit to a protocol. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ insights — mapping FTO, FOXO3, SHBG, COMT, and other variants so your provider can calibrate protocol decisions to your actual biology rather than generic defaults.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.